1] Monter Cancer Center, NorthShore LIJ, 450 Lakeville Road, Lake Success, NY 11040, USA [2] Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA.
The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA.
Br J Cancer. 2014 Feb 18;110(4):976-83. doi: 10.1038/bjc.2013.795. Epub 2013 Dec 24.
Securing a diagnosis of ovarian cancer and establishing means to predict outcomes to therapeutics remain formidable clinical challenges. Early diagnosis is particularly important since survival rates are markedly improved if tumour is detected early.
Comprehensive miRNA profiles were generated on presurgical plasma samples from 42 women with confirmed serous epithelial ovarian cancer, 36 women diagnosed with a benign neoplasm, and 23 comparably age-matched women with no known pelvic mass.
Twenty-two miRNAs were differentially expressed between healthy controls and the ovarian cancer group (P<0.05), while a six miRNA profile subset distinguished presurgical plasma from benign and ovarian cancer patients. There were also significant differences in miRNA profiles in presurgical plasma from women diagnosed with ovarian cancer who had short overall survival when compared to women with long overall survival (P<0.05).
Our preliminary data support the utility of circulating plasma miRNAs to distinguish women with ovarian cancer from those with a benign mass and identify women likely to benefit from currently available treatment for serous epithelial ovarian cancer from those who may not.
确诊卵巢癌并建立预测治疗结果的方法仍然是极具挑战性的临床难题。早期诊断尤为重要，因为如果早期发现肿瘤，患者的存活率会显著提高。
对 42 名经证实患有浆液性上皮性卵巢癌的女性、36 名被诊断为良性肿瘤的女性和 23 名年龄匹配的无盆腔肿块的女性的术前血浆样本进行了全面的 miRNA 谱分析。
22 个 miRNA 在健康对照组和卵巢癌组之间存在差异表达（P<0.05），而由 6 个 miRNA 组成的亚群可以区分术前血浆与良性和卵巢癌患者。在诊断为卵巢癌的女性中，术前血浆的 miRNA 谱也存在显著差异，与总体生存时间较长的女性相比，总体生存时间较短的女性（P<0.05）。
我们的初步数据支持循环血浆 miRNA 可用于区分卵巢癌患者和良性肿块患者，并识别出可能从目前可用的浆液性上皮性卵巢癌治疗中获益的患者和可能无法获益的患者。
